Technical Articles

Based on the clinical treatment challenges of rhabdomyosarcoma (RMS), this article systematically elaborates on the high expression characteristics of fibroblast growth factor receptor 4 (FGFR4) in RMS and other malignant tumors, as well as its theoretical basis as an immunotherapy target. It analyzes the antitumor activity of FGFR4-targeted antibody-drug conjugates (ADCs) in preclinical studies and their potential advantages compared to CAR-T cell therapy.